NCT04678089

Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics

Evaluating Study of Clinical Treatment of Multiple Myeloma Based on Analytical Omics

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 350 (estimated)
• Sponsor: Beijing Chao Yang Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Accepted

Summary

With the emergence of new drugs, the short-term survival rate of multiple myeloma has been significantly increased. However, in clinical treatment, doctors found that different patients may present different clinical efficacy and adverse reactions when using standard treatment. Some studies have shown that gene and metabolic differences in patients with multiple myeloma may be an important factor affecting clinical efficacy. In this project, peripheral blood samples and bone marrow from patients with multiple myeloma will be studied by using the methods of genomics, proteomics, metabonomics and transcriptomics. It is expected to find biomarkers and genes related to clinical efficacy, adverse reactions, and blood concentration of bortezomib in peripheral blood samples. If the sample size is large enough, the project team expects to establish a prediction model for the efficacy and safety of bortezomib containing regimen for multiple myeloma patients through the above studies. Investigators hope that the evaluation system can provide a reference for clinical formulation of appropriate drug delivery scheme.

Conditions

• Multiple Myeloma
• Bortezomib

Interventions

Type	Name	Description
DRUG	Bortezomib	Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc

Timeline

• Start date: 2019-05-16
• Primary completion: 2022-12-01
• Completion: 2023-12-01
• First posted: 2020-12-21
• Last updated: 2022-04-28

Locations

1 site across 1 country: China